Light-Stimulated Insulin Production in Diabetic Mice

Fan Zhang and Emmanuel S. Tzanakakis, working at Tufts University, reported in ACS Synthetic Biology (vol. 8, issue 10, pp. 2248–2255) that pancreatic beta-cells engineered to express a photoactivatable adenylyl cyclase released more than twice the baseline amount of insulin when exposed to blue light, but only in the presence of glucose. The cells did not leak insulin in low-glucose conditions, which matters: a light-controlled therapy that ignored blood glucose would create the same hypoglycemia risks that injected insulin already poses.

When the team transplanted these engineered cells into mice that had been chemically induced to lose their native beta-cells (the streptozotocin model of type 1 diabetes), illuminating the implant lowered hyperglycemia, improved glucose tolerance, and raised plasma insulin compared to the unilluminated controls.

The mechanism is built around cyclic AMP (cAMP), the second messenger that potentiates glucose-stimulated insulin secretion. Beta-cells normally elevate cAMP through G-protein-coupled receptors after a meal, which amplifies their response to rising blood glucose. The Tufts team replaced that receptor input with a light-driven enzyme, photoactivatable adenylyl cyclase, that produces cAMP when struck by blue light around 470 nm.

Stable expression of the photoactivatable adenylyl cyclase in the beta-cell line meant the trigger sat upstream of the natural insulin-release machinery. Blue light raised cAMP; cAMP amplified glucose-driven insulin secretion; the cell still required glucose to release the hormone. The oxygen consumption rate of the cells did not shift under illumination, which suggests the light pulse worked through the signaling pathway and not through a stress or metabolic side effect.

Insulin therapy in 2019 was either pump-delivered or injected. Both rely on the patient or a closed-loop algorithm to dose correctly, and both can overshoot. Cell-based therapies (transplanted islets, stem-cell-derived beta-cells) had been in the pipeline for years but lacked a tunable rheostat: once transplanted, the cells secrete on their own schedule.

Optogenetic control offered a third axis. The clinician sets a light source, the cells respond when both light and glucose are present, and the patient retains the safety floor of glucose-dependent secretion. The Zhang and Tzanakakis paper was the first to show this loop closing in a living diabetic animal rather than in a dish.

The 2019 paper has since been cited across the optogenetic-medicine literature. Three follow-ups stand out:

• Frank et al., 2021 (Small) showed that a smartphone flashlight could trigger insulin release in engineered cells implanted under the skin of diabetic mice, restoring glucose homeostasis. The piece moved the trigger from a laboratory laser to a consumer device.
• Kushibiki et al., 2023 (Molecular Therapy) extended light-stimulated secretion to islet-like organoids derived from human pluripotent stem cells, an important step toward a translational graft material.
• Zhang et al., 2024 (ACS Synthetic Biology), from the same Tufts group, demonstrated light-mediated enhancement of glucose-stimulated insulin release in optogenetically engineered human beta-cells, building directly on the 2019 murine work.

Reviews in Diabetes (2024), Journal of Diabetes (2024), and Current Opinion in Biotechnology (2025) trace the broader trajectory.

If you are running an optogenetic experiment that depends on blue-light activation of an enzymatic switch, the dose at the cell surface matters. Wavelength, irradiance, and exposure time all shape the response, and an underdosed pulse looks like a failed construct. Our irradiance calculator handles the geometry: source power, distance, beam profile, and target area, returning the photon flux at the cell layer.

• Zhang F, Tzanakakis ES. Amelioration of Diabetes in a Murine Model upon Transplantation of Pancreatic β-Cells with Optogenetic Control of Cyclic Adenosine Monophosphate. ACS Synthetic Biology. 2019;8(10):2248–2255. DOI: 10.1021/acssynbio.9b00262. PMID: 31518106.
• Tufts University release via EurekaAlert, November 2019: Engineering cells to use light to control blood sugar.